NEW YORK (GenomeWeb News) – Phosphoproteomics firm Activiomics today announced a technology agreement with biopharmaceutical company UCB to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
Under the collaborative deal, Activiomics will use its mass spectrometry-based Targeted In-Depth Quantification of cell Signaling (TIQUAS) platform to analyze and interpret cell-signaling pathway activity, which will generate "high-value information" for the pharmaceutical and biotechnology industry, the London-based company said in a statement.
Financial and other terms of the deal were not disclosed.
According to Activiomics' website, TIQUAS quantifies global kinase activity without a need for labeling or antibody isolation. It works by using a protease to break down a cell or tissue extract into peptide fragments. Phosphopeptide enrichment, mass spectrometry, and TIQUAS software allow thousands of phosphopeptides to be quantified.
Simon Lumb, project leader at UCB said, the technology will allow the Belgian firm to "better understand cell signaling mechanisms of our therapeutic antibodies and could enable us to identify important biomarkers."